
Opinion|Videos|January 22, 2024
The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
Author(s)Virginia G. Kaklamani, MD
Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































